Ekso Bionics (EKSO) Earns Coverage Optimism Score of 0.16
News stories about Ekso Bionics (NASDAQ:EKSO) have been trending somewhat positive on Thursday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ekso Bionics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.1774566972916 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Traders Alert: Star Bulk Carriers Corp., (NASDAQ: SBLK), Ekso Bionics Holdings, Inc., (NASDAQ: EKSO), M&T Bank … – Stocks In The News (press release) (tradingnewsnow.com)
- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Is P/E & PEG The Same Thing – Nasdaq Journal (press release) (nasdaqjournal.com)
- Healthcare Robots Industry Insights With Key Company Profiles – Demand, Analysis, Forecast To 2024 (it.tmcnet.com)
- Ekso Bionics Holdings, Inc. (EKSO) Grabs Dynamic Performance Momentum on Volatility – Stock News Stop (stockmarketstop.com)
- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Eye-Catching Hot Stocks – Nasdaq Journal (press release) (nasdaqjournal.com)
Ekso Bionics (NASDAQ:EKSO) traded down $0.24 during trading on Thursday, reaching $2.32. 1,345,300 shares of the company were exchanged, compared to its average volume of 928,317. Ekso Bionics has a fifty-two week low of $0.99 and a fifty-two week high of $4.77. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18.
Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $2.40 million. sell-side analysts forecast that Ekso Bionics will post -0.81 EPS for the current year.
A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Ekso Bionics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th. ValuEngine upgraded shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.
In other news, insider Russ Angold sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.32% of the stock is owned by insiders.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.